Welcome to our dedicated page for Dyadic Intl Del news (Ticker: DYAI), a resource for investors and traders seeking the latest updates and insights on Dyadic Intl Del stock.
Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions reports developments tied to its biotechnology platforms for producing precision-engineered recombinant proteins and enzymes. The company uses proprietary microbial expression systems, including C1 and Dapibus, to serve life sciences, food and nutrition, and industrial biotechnology applications through product sales, licensing, and partner commercialization.
Recurring news includes financial results, corporate update calls, commercial launches, distribution agreements, and development collaborations. Company updates have covered recombinant human albumin, animal-origin-free recombinant DNase I, transferrin, bovine alpha-lactalbumin, non-animal dairy enzymes, and broader portfolios for cell culture, molecular biology, nutrition, and bioindustrial markets.
Dyadic (NASDAQ: DYAI) reported Q1 2026 revenue of $1.11 million, up 182.3% year over year, with net loss narrowing to $1.95 million or $(0.05) per share. Cash and securities were $6.6 million on March 31, 2026.
The company highlighted commercial launches and agreements across life sciences, food and nutrition, and bio-industrial markets, including products such as recombinant albumin, DNase I, transferrin, alpha-lactalbumin and non-animal chymosin, plus progress in Gates Foundation and CEPI-supported biopharmaceutical programs.
Dyadic (Nasdaq: DYAI) will report Q1 2026 financial results and host a corporate update conference call on Wednesday, May 13, 2026 at 5:00 p.m. ET. The live dial-in and webcast details are provided below; an archived replay will be available within 24 hours on the company's Investor Relations website.
Dial-in numbers: Toll Free +1-877-407-9219 / +1-412-652-1274. Conference ID: 13759380. Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=qVNgtGJ6. Submit Q&A questions in advance to jlavalley@dyadic.com.
Dyadic Applied BioSolutions (NASDAQ: DYAI) reported 2025 results and announced multiple commercial agreements and product launches. Key financials: cash ~$8.59M, total revenue $3.09M (2025 vs $3.50M 2024), and net loss $7.36M or $(0.23) per share.
Commercial progress includes the commercial launch of AlbuFree™ DX with Proliant, launch of RNase-free DNase I with Fermbox, an OEM distribution deal with IBT Bioservices, and a BRIG Bio agreement for recombinant alpha-lactalbumin.
Dyadic (NASDAQ: DYAI) announced an OEM distribution agreement with IBT Bioservices on March 16, 2026 to commercialize Dyadic-produced recombinant proteins for research-use-only applications. Initial products include recombinant DNase I and recombinant transferrin (human and bovine), leveraging IBT’s global sales channels to expand market access.
The collaboration complements Dyadic’s manufacturing and portfolio expansion, supports the company’s shift toward product-based revenues, and allows flexibility for future distribution, licensing of production strains, or partner-led manufacturing.
Dyadic (Nasdaq: DYAI) will report full year 2025 financial results and host a corporate update conference call on Wednesday, March 25, 2026 at 5:00 p.m. ET.
The live call will use dial-in numbers and a webcast; an archive will be available within 24 hours on the company's Investor Relations website. Investors may submit Q&A questions in advance by email.
Dyadic (NASDAQ: DYAI) and Fermbox Bio launched an animal-origin-free Recombinant DNase I (RNase-free) on March 4, 2026, the first commercial product under their expanded collaboration.
The product is available in research grade now; a cGMP-grade version is in development to support biopharma and cell and gene therapy manufacturing. The launch signals Dyadic's move toward commercial product expansion and recurring revenue growth, with more recombinant proteins planned for rollout through 2026 under the partnership.
Dyadic Applied BioSolutions (NASDAQ: DYAI) and Inzymes ApS announced planned 2026 commercialization of recombinant non-animal bovine chymosin for cheese production after completing final development activities.
Dyadic received a $200,000 milestone payment and remains eligible for royalties on future commercial sales; the global dairy processing enzyme market is estimated at $1.5–$2.0 billion annually.
Dyadic Applied BioSolutions (NASDAQ: DYAI) and Proliant Health & Biologicals announced the commercial launch of AlbuFree™ DX, a recombinant human albumin (rHA) product produced using Dyadic’s filamentous fungal expression technology on Feb 17, 2026.
Under the agreement, Dyadic will receive a share of profits from Proliant’s commercial sales. Proliant plans an expanded AlbuFree™ line later in 2026, including a formulation targeted for the cell culture market. Dyadic said the launch advances its strategy to convert licensed programs into recurring revenue and validates its microbial platform for scalable, animal-free protein production.
Dyadic (NASDAQ: DYAI) announced an expansion of its strategic collaboration with Fermbox Bio to broaden manufacture, commercialization, and dual-sourcing of Dyadic-developed animal-free proteins and enzymes across life science, food & nutrition, and bioindustrial markets.
Key elements include Fermbox manufacturing multiple Dyadic-origin products at commercial scale, co-commercialization rights globally, inclusion of Fermbox-developed products into the joint portfolio, dual-sourcing via C1, Dapibus™ or alternative microbial systems, and a jointly managed, continuously updated product pipeline to accelerate development and shorten commercialization timelines.
Dyadic Applied BioSolutions (NASDAQ: DYAI) announced a commercial agreement with Opes Diagnostics Limited on Dec 15, 2025 to support the launch of Dyadic’s recombinant human transferrin, bovine transferrin, human FGF, and bovine FGF for serum-free cell culture media applications.
Opes will leverage existing commercial relationships to identify customers primarily in Europe, Israel, and Asia, while Dyadic retains direct-selling rights and can work with other partners. The collaboration aims to accelerate adoption across research, diagnostics, cultured meat, and biomanufacturing markets.